ライフサイエンスコーパス: medication adherence

1 self-efficacy), and health behaviors (e.g., medication adherence).

2 outine care, and has reproducible effects on medication adherence.

3 tection appears to be highly correlated with medication adherence.

4 dge of glaucoma, and perceptions of glaucoma medication adherence.

5 that are optimized for clinic retention and medication adherence.

6 een developed to simplify dosing and improve medication adherence.

7 ess, treatment, control, or antihypertensive medication adherence.

8 social predictors that will lead to improved medication adherence.

9 ife chaos may be an important determinant of medication adherence.

10 this high-risk patient population to improve medication adherence.

11 multiple sources of information to quantify medication adherence.

12 eases in sexual risk despite low to moderate medication adherence.

13 s, reduced out-of-pocket costs, and improved medication adherence.

14 ther 95% or greater or less than 95% overall medication adherence.

15 e, and finally, (5) interventions to improve medication adherence.

16 of the copayment increase on lipid-lowering medication adherence.

17 less of whether patients had good or poor BP medication adherence.

18 sion control in diabetes care independent of medication adherence.

19 nly 35% of bipolar adolescents reported full medication adherence.

20 ractures, fracture rates and disutility, and medication adherence.

21 atient visits, and negative attitudes toward medication adherence.

22 , and biologic variables on antihypertensive medication adherence.

23 d model included the additional covariate of medication adherence.

24 relapse, depressive and manic symptoms, and medication adherence.

25 a, knowledge is limited about how to improve medication adherence.

26 ment of strategies to establish and maintain medication adherence.

27 coping strategies and counseling to improve medication adherence.

28 nt of education, perceived stress, race, and medication adherence.

29 ecutive function, or memory predicted 21-day medication adherence.

30 with worse short-term and long-term patient medication adherence.

31 iated through the effects of cannabis use on medication adherence.

32 flicts with participants' own high rating of medication adherence.

33 subjective well-being and immunosuppressive medication adherence.

34 distributed through daily lotteries tied to medication adherence.

35 ypertensive medications and interfering with medication adherence.

36 tient relationships, patient engagement, and medication adherence.

37 ts were largely consistent when adjusted for medication adherence.

38 bout their health and their attitudes toward medication adherence.

39 rug treatment plan are associated with lower medication adherence.

40 subgroup analysis by anatomic location, and medication adherence.

41 onent of the treatment, we also searched for medication adherence." 2.

42 those taking medications reported increased medication adherence; 26% to 36% had privacy concerns; 1

43 a result of the multiple factors influencing medication adherence, a patient-centered approach that t

44 f opioid dependence is limited by suboptimal medication adherence, abuse, and diversion.

45 dabigatran, there was variability in patient medication adherence across Veterans Health Administrati

46 atients and by clinicians is associated with medication adherence, adjusting for clinician clustering

47 impact of patient-provider communication on medication adherence among a sample of primary care prov

48 examine the impact of cognitive function on medication adherence among community-dwelling patients w

49 ng data (n = 1,817) from the Cohort Study of Medication Adherence among Older Adults (recruitment con

50 ially in regard to memory, predicted reduced medication adherence among patients with HF and no histo

51 here remain opportunities for improvement in medication adherence among patients with prescription dr

52 Evidence-based interventions to improve medication adherence among patients with schizophrenia a

53 idence-based nursing intervention to improve medication adherence among people living with HIV/AIDS a

54 t increase adversely affected lipid-lowering medication adherence among veterans, including those at

55 ng were related to subjective well-being and medication adherence among young adult kidney transplant

56 herence to medication regimens (hereinafter "medication adherence") among older adults after MI.

57 e objectives of the study were to (a) assess medication adherence and (b) to identify emotionality an

58 Secondary outcomes included both medication adherence and a composite end point of all-ca

59 roups received behavioral therapy focused on medication adherence and a second dose of XR-naltrexone.

60 atherosclerosis by 25% by 2025 by improving medication adherence and access, but further trial data

61 sease, providers should identify barriers to medication adherence and actively engage patients in sha

62 multifactorial intervention to improve both medication adherence and blood pressure control and to r

63 Counseling of patients with CHB on medication adherence and confirmation of VBT and/or GR c

64 f the intervention is effective in improving medication adherence and demonstrating a lower cost, the

65 s that programs are feasible and may improve medication adherence and disease outcomes.

66 etrimental effects of release from prison on medication adherence and disease progression among HIV-p

67 Treatments that emphasize medication adherence and early recognition of mood sympt

68 on, and pharmaceutical databases may improve medication adherence and have a positive effect on cardi

69 s have highlighted the importance of patient medication adherence and have outlined factors that affe

70 es are broadly applicable or affect longterm medication adherence and health outcomes.

71 blood pressure (BP) control because of poor medication adherence and lack of medication intensificat

72 To assess the association between medication adherence and medical homes in a national pat

73 Objective: To assess the association between medication adherence and medical homes in a national pat

74 sideration of DDIs is paramount to improving medication adherence and mitigating adverse effects duri

75 nt outcomes by reinforcing the importance of medication adherence and persistence and by recognizing

76 s provided limited and heterogeneous data on medication adherence and persistence.

77 of the program was associated with decreased medication adherence and persistence.

78 Improvements in medication adherence and prescribing could have a substa

79 Enhanced prescription coverage improved medication adherence and rates of first major vascular e

80 Medication adherence and relapse rates are similar acros

81 Medication adherence and treatment intensification have

82 To date, measurement of patient medication adherence and use of interventions to improve

83 riant (other illicit drug use, antipsychotic medication adherence) and time-invariant (eg, genetic or

84 changes in diabetes distress, self-efficacy, medication adherence, and hemoglobin A1c values.

85 ncluding depression, provider relationships, medication adherence, and HIV-1 viral load.

86 bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms th

87 ivation, sex- and age-related differences in medication adherence, and sex-related differences in bod

88 ry, improving cost-effectiveness, increasing medication adherence, and supporting a comprehensive pre

89 The odds of poor medication adherence are greater when patient-provider i

90 tcome data for patients with gout, including medication adherence, are limited.

91 Participants who reported low importance of medication adherence as a personal goal were more likely

92 ticipants in each study (in particular about medication adherence), as well as whether pharmacologic

93 studies (e.g. pharmacokinetic evaluations or medication adherence assessment) since it is minimally i

94 ar events (death, recurrent MI, stroke), and medication adherence at 1 year.

95 sual care resulted in significantly improved medication adherence at 15 months and statistically sign

96 Morisky instrument to assess cardiovascular medication adherence at 6 weeks post MI, we stratified p

97 than 6 weeks remained associated with lower medication adherence at 90 days (odds ratio [OR], 0.74 [

98 al attainment and lack of autonomy regarding medication adherence at transition.

99 ect Schedule; Satisfaction With Life Scale), medication adherence (Basel Assessment of Adherence to I

100 His medication adherence became erratic, and he missed appoi

101 t posttransplantation acute organ rejection, medication adherence becomes a key factor for successful

102 ocial variables, memory continued to predict medication adherence (beta=0.51; P=0.008), whereas execu

103 on all 3 cognitive domains predicted poorer medication adherence (beta=0.52-85; P=0.001-0.009).

104 ty presenting with MI have superior rates of medication adherence but higher rates of postdischarge r

105 he causal pathway linking health literacy to medication adherence by modeling asthma illness and medi

106 ed technology-based interventions to improve medication adherence by using pharmaceutical databases,

107 Secondary outcomes were study medication adherence (by self-report and medication even

108 ibutes included age, sex, employment status, medication adherence, comorbidity status, and geographic

109 Interventions directed at medication adherence could partly help mitigate the harm

110 t, health education, treatment readiness and medication adherence counseling, and medication coordina

111 pants were followed monthly to provide study medication, adherence counseling, and HIV testing.

112 and individually tailored risk-reduction and medication-adherence counseling.

113 Medication adherence data were collected continuously du

114 e claims data to obtain 1-year follow-up and medication adherence data.

115 nths after randomization, the persistence of medication adherence decreased to 69.1% (16.4%) among th

116 In Phase 1, overall CV medication adherence, defined as an MAQ score of 20, was

117 nsplantation, patients (n=44) with declining medication adherence, defined as dropping by 7% or highe

118 Medication adherence, defined as having medications avai

119 rapy; blood pressure; and patient reports of medication adherence, diabetes-related support, and emot

120 Poor medication adherence diminishes the health benefits of p

121 eness of methods to improve antihypertensive medication adherence, discusses the effect of drug benef

122 The relationships of study medication adherence, dosage, and cumulative exposure (p

123 n cost-saving even if strategies to increase medication adherence doubled treatment costs.

124 ART initiation and prenatal care, along with medication adherence during pregnancy, were associated w

125 uctions in mood disorder symptoms and better medication adherence during the 2 years than patients un

126 approach compared changes in lipid-lowering medication adherence during the 24 months before and aft

127 o describe the types of objectively measured medication adherence (eg, taking, timing, dosing, drug h

128 death-censored graft loss.In addition, daily medication adherence, expressed as the percentage of dos

129 ly telephone monitoring of mood symptoms and medication adherence, feedback to treating mental health

130 ned psychosocial interventions for improving medication adherence, focusing on promising initiatives,

131 We performed a prospective cohort study of medication adherence, followed by a randomized intervent

132 months 1 and 2, later experienced lower mean medication adherence for months 6 to 12, 73% versus 92%

133 ucation with behavioral support all improved medication adherence for more than 1 condition.

134 Rates of medication adherence for secondary prevention therapies

135 Patients' prior medication adherence had little impact on providers' dec

136 less of coronary revascularization strategy, medication adherence has a dramatic effect on long-term

137 to 6 weeks had no significant difference in medication adherence; however, patients with follow-up m

138 t of the adapted intervention, self-reported medication adherence improved significantly in the group

139 o help to prevent HIV infection, and improve medication adherence in HIV/AIDS.

140 ion between life events and antihypertensive medication adherence in older adults and the moderating

141 ntions designed to improve asthma controller medication adherence in older adults may be enhanced by

142 Pharmacy refill records were used to compare medication adherence in outpatient veterans receiving ty

143 treatment of depressive symptoms may improve medication adherence in patients after ACS.

144 adversely affecting the quality of life and medication adherence in patients with cancer in the USA.

145 Many factors are associated with the lack of medication adherence in patients.

146 are not likely to be effective in improving medication adherence in schizophrenia.

147 Reminders from medication monitors improved medication adherence in TB patients, but text messaging

148 messaging and medication monitors to improve medication adherence in TB patients.

149 ctiveness of a medication monitor to improve medication adherence in TB patients.

150 Medication adherence in the 12 months after treatment in

151 Measurements: Medication adherence in the 12 months after treatment in

152 After 6 months of intervention, medication adherence increased to 96.9% (5.2%; P<.001) a

153 ing conditions increased, and more likely as medication adherence increased.

154 haracteristics, barriers to optimal glaucoma medication adherence, interest in an eye drop aid, and s

155 Poor medication adherence is a pervasive problem in patients

156 Suboptimum medication adherence is common in the United States and

157 Excellent posttransplant medication adherence is critical to improved outcomes.

158 These data support the concept that medication adherence is modifiable via improved care tra

159 empirical support for its ability to enhance medication adherence is scarce.

160 The effect of more generous drug coverage on medication adherence is uncertain.

161 ted through an adverse effect of cannabis on medication adherence is unclear.

162 The influence of life chaos on medication adherence is unknown.

163 udy was to determine the association between medication adherence levels and long-term MACE in these

164 talizations (moderate-strength evidence) and medication adherence (low-strength evidence) compared wi

165 atient-provider communication predicted poor medication adherence: lower patient centeredness (odds r

166 Lower medication adherence may be associated with a higher ris

167 A pharmacy care program led to increases in medication adherence, medication persistence, and clinic

168 Interventions to improve medication adherence must address each patient's unique

169 ys." A patient subgroup with early declining medication adherence (n=23) experienced dramatically poo

170 predict the prognosis of patients and ensure medication adherence of patients with CSU.

171 This measure was also used to assess medication adherence on the basis of both face-to-face i

172 s, as are lifestyle counseling, promotion of medication adherence, ongoing lipid surveillance, and me

173 nt domains can be achieved through increased medication adherence or new therapeutic strategies.

174 he non-crossover group may reflect decreased medication adherence or other related factors.

175 of the 98 patients were not classified as to medication adherence or plasma levels.

176 not differ in blood pressure, self-reported medication adherence, or diabetes-specific distress, but

177 pharmacy refill data to examine patients' BP medication adherence over the prior 12 months and whethe

178 lled structural equation modelling analyses, medication adherence partly mediated the effect of conti

179 ation modelling analysis to estimate whether medication adherence partly mediated the effects of cont

180 Prospectively, individual medication adherence patterns in 195 kidney transplant r

181 ciaries, GBTM identified 5 distinct glaucoma medication adherence patterns in both the 1-year and 4-y

182 patients who were newly prescribed glaucoma medications, adherence patterns observed in the first ye

183 depression increases mortality and decreases medication adherence, physicians need to aggressively tr

184 Depression may be an important cause of medication adherence problems, and difficulties with adh

185 Quality-of-care measures included medication adherence, psychotherapy, and follow-up visit

186 ation of combination antiretroviral therapy, medication adherence, race, and depression status were r

187 }, 1.7-3.3]; P < .001) after controlling for medication adherence, race/ethnicity, baseline CD4 cell

188 derstood, including the possible role of low medication adherence rates that have been found in other

189 Functional Health Literacy in Adults and the Medication Adherence Rating Scale, respectively.

190 t commitment had its effect through improved medication adherence, reduced substance use or abuse, an

191 of in-person contacts with technology-driven medication adherence reminders, electronic medication re

192 Recent data suggest that the level of medication adherence required for optimal treatment effe

193 as scores less than 6 on the 8-item Morisky Medication Adherence Scale (known as "MMAS-8").

194 was assessed using the 8-question (c)Morisky Medication Adherence Scale (MMAS-8).

195 Adherence was assessed using Morisky Medication Adherence Scale - 8 and adherence determinant

196 s were developed based on the 8-item Morisky Medication Adherence Scale and administered to 2 academi

197 Adherence was assessed with a self-reported medication adherence scale and IS blood trough concentra

198 ucoma medications and self-reported glaucoma medication adherence self-efficacy and (b) examine the r

199 ssess patient reported problems and glaucoma medication adherence self-efficacy and work with patient

200 minister glaucoma drops and patient glaucoma medication adherence self-efficacy are associated positi

201 System (MEMS) devices, and general glaucoma medication adherence self-efficacy using a previously va

202 Higher glaucoma medication adherence self-efficacy was associated positi

203 medications had significantly lower glaucoma medication adherence self-efficacy.

204 onger reported significantly higher glaucoma medication adherence self-efficacy.

205 e reliability and concurrent validity of the Medication Adherence Self-report Inventory (MASRI) when

206 fectiveness and costs, monitoring frequency, medication adherence, side effect severity, background h

207 are needed to improve retention in care and medication adherence so that more persons in HIV care ac

208 symptoms, perceived control, social support, medication adherence, sodium intake, and self-care manag

209 teristics, illness history, clinical status, medication adherence, substance abuse, insight into illn

210 nt, MFG-adherence was associated with higher medication adherence than MFG-standard or treatment as u

211 n between patient-provider communication and medication adherence, there are no empirical data on how

212 oup therapy specifically tailored to improve medication adherence through a focus on the beliefs and

213 services, retain women in care, and support medication adherence throughout pregnancy and breastfeed

214 The benefits of medication adherence to control cardiovascular disease (

215 ubjects' reported problems in using glaucoma medications, adherence to glaucoma medications utilizing

216 Secondary outcomes were rates of medication adherence, total major vascular events or rev

217 d with or without CABG, leading to increased medication adherence, trends toward improved clinical ou

218 o changes in self-reported immunosuppressive medication adherence up to 18 months after transplantati

219 For each enrollee, we quantified medication adherence using the medication possession rat

220 We measured health literacy and medication adherence using the Short Test of Functional

221 Medication adherence usually refers to whether patients

222 Mean (SD) baseline medication adherence was 61.2% (13.5%).

223 During the 9-month intervention period, medication adherence was 67.9% and 78.8% in the usual ca

224 Medication adherence was 97% by self-report, 96% by pill

225 When medication adherence was added as covariate, the valproa

226 Medication adherence was assessed as a mediator variable

227 Medication adherence was assessed using the 8-question (

228 Medication adherence was associated with prevention of e

229 Medication adherence was defined as the proportion of da

230 patients' sociodemographic circumstances on medication adherence was heightened in black patients (o

231 Medication adherence was measured for each patient by ob

232 Medication adherence was objectively measured for 21 day

233 matched control and medical home practices, medication adherence was significantly higher in medical

234 had treatment interruptions or reported poor medication adherence were more likely to have detectable

235 Limitation: Clinical outcomes related to medication adherence were not assessed.

236 To summarize recent literature regarding medication adherence with a focus on the complexities in